Lirentelimab for Antihistamine-Refractory Chronic Spontaneous Urticaria – Phase 2 Trial in Progress

Marcus Maurer MD^{1,2}, Martin Metz MD¹, Hanna Bonnekoh MD¹, Frank Siebenhaar MD¹, Alan T. Chang³, Rita DeVico³, Enoch Bortey PhD³, Cristian Rodriguez MD³, Craig Paterson MD³

NCT05528861 "MAVERICK"

¹Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany; ³Allakos Inc., San Carlos, CA, USA

BACKGROUND

- Current treatment guidelines for the management of all forms of chronic urticaria (CU) recommend the use of a non-sedating second generation oral H1antihistamine (sgAH) as first-line therapy¹
- In more than 50% of sgAH-treated patients, symptoms persist despite the use of up to 4 times the licensed dose^{1,2}
- In sgAH-refractory patients with chronic spontaneous urticaria (CSU), the only licensed treatment available is omalizumab, a monoclonal anti-IgE antibody³
- Despite omalizumab treatment, a substantial number of patients do not respond^{3,4}

STUDY POPULATION

 Adult (18-80 years) subjects with moderate-to-severe CSU inadequately controlled by sgAH are eligible for screening for the study

Key Inclusion Criteria:

- CSU diagnosis for \geq 6 months
- Diagnosis of moderate-severe CSU refractory to sgAH:
- Presence of hives and itch for ≥ 6 consecutive weeks prior to Screening;
- UAS7 score (range 0–42) ≥16 and HSS7 score (range 0–21) ≥8
- Subjects that are omalizumab-naïve or omalizumab-exposed


Figure 3. MAVERICK Study Schema (Randomized Period)	 ↓ Study Visit ↓ Follow-up Visit ▲ SC Administration
Follow L	e-Blind Jp Period /eeks)
Placebo SC Q2W Optional 6	or puid dose OLE iii
↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	<u> </u>
~3 Weeks	
Timepoint:	

New and targeted treatments are needed

STUDY RATIONALE

 CSU is a mast cell (MC) driven disease¹ • Lirentelimab (AK002)^{*} is a humanized IgG1 mAb directed against Siglec-8, which is expressed selectively on MCs and eosinophils, inhibits MCs and depletes eosinophils^{5,6}

Figure 1. Lirentelimab (AK002) Mechanism of Action



• Lirentelimab, administered every 4 weeks as an infusion (IV), has been tested in over 700 healthy volunteers and patients with inflammatory and allergic diseases⁷⁻¹⁰

Subjects must be on a stable dose of sgAH, between $1 \times$ and $4 \times$ the licensed dose and frequency, for treatment of CSU for at least 1 week prior to screening

Key Exclusion Criteria:

- Current use of biologics for any indication
- Demonstrated lack of primary response to treatment with a biologic therapy (e.g., omalizumab) for the treatment of CSU
- Use of any of the following treatments need to be stopped prior to the study: immunosuppressive or immunomodulatory drugs; systemic hydroxychloroquine; intravenous immunoglobulin (IVIG); plasmapheresis; oral Janus kinase (JAK) inhibitors; H2-AH; and LTRA
- sgAH use at greater than approved doses or greater than local CSU guideline recommended doses
- Subjects having causes other than CSU for their urticaria including symptomatic dermographism, cholinergic urticaria, or any inducible urticaria
- Diseases other than CU with urticarial or angioedema symptoms, including chronic itching, that in the Investigator's opinion might influence study evaluations and results

Day:	1 8 15	29	43	57	71	85	127	155
Week:	0 1 2	4	6	8	10	12	18	22
SC Injection:		•			•	F/U 1	F/U 2	F/U 3 EOS

Table 1. Key Efficacy Measures in MAVERICK


Full Name of Measure	Approach
UAS: Urticaria Assessment Score	Patient questionnaire
HSS: Hives Severity Score	Patient questionnaire
ISS: Itch Severity Score	Patient questionnaire
UCT: Urticaria Control Test	Physician interview
DLQI: Dermatology Life Quality Index	Patient questionnaire

STUDY SITES

Figure 4. Current MAVERICK Study Sites in the US and Germany

- Overall, lirentelimab IV has been well-tolerated; the most common AE being infusion related reactions (IRRs) typically associated with the initial infusion
- In a phase 1 study, a subcutaneous (SC) formulation of lirentelimab was well-tolerated with no IRRs¹⁰
- In an open-label phase 2a proof-of-concept study, IV lirentelimab demonstrated a clinical response in patients with sgAH-refractory CSU, naïve or refractory to omalizumab⁹

Figure 2. Change in UAS7 with Lirentelimab in the Phase 2a Proof-of-Concept Study⁹



STUDY DESIGN

- Approximately 110 subjects with sgAH-refractory CSU will be randomized 1:1 to receive either
- -6 SC injections of 300mg lirentelimab every 2 weeks
- -6 doses of placebo SC every 2 weeks
- Subjects will be stratified at randomization based on omalizumab experience for the treatment of CSU (exposed/naïve) and weekly Urticaria Activity Score (UAS7) values (16-27 or 28-42)
- Subjects who complete the double-blind period of the study, contingent on meeting defined study selection criteria, will be given the option to enroll in an openlabel extension (OLE) for 6 doses of 300mg lirentelimab SC
- All subjects will be followed for approximately 12 weeks after the last dose in the double-blind period
- All patients who receive study medication will be included in the safety analysis

Primary Efficacy Objective:

12

Absolute change in UAS7 from baseline to Week



 This study is planning to enroll from ~70 sites in the USA and Europe

^a Patients who received 6 doses ***P*<0.01, ****P*<0.001

• The results of these studies provide a strong rationale for conducting this phase 2 randomized, double-blind trial of lirentelimab SC in omalizumab-naïve and omalizumab-exposed adults with moderate-severe sgAH-refractory CSU (NCT05528861, "MAVERICK")

Key Secondary and Exploratory Objectives:

- Absolute change in weekly Hives Severity Score (HSS7) from baseline to Week 12
- Absolute change in weekly Itch Severity Score (ISS7) from baseline to Week 12
- Proportion of subjects achieving UAS7 = 0 at Week 12
- Proportion of subjects achieving UAS≤6 at weeks 12 and 22
- Change in UCT score at Week 12
- Proportion of subjects achieving Dermatology Life Quality Index (DLQI) = 0 or 1

CONCLUSION/DISCUSSION

- In a proof-of-concept trial, lirentelimab was well tolerated and demonstrated clinical activity in omalizumab-naïve and omalizumab-refractory patients with CSU
- Lirentelimab represents a potential novel approach to treat patients with CSU who are refractory to the standard care of non-sedating second generation oral H1-antihistamines
- This phase 2 randomized, double-blind trial of lirentelimab SC in omalizumab-naïve and omalizumab-exposed adults with moderatesevere sgAH-refractory CSU is currently enrolling! Please visit clinicaltrials.gov (NCT05528861) or email maverick.info@allakos.com to learn more

*Lirentelimab is an investigational medicine, its efficacy and safety profile have not been established, and it has not been approved by the FDA.

References: (1) Zuberbier T, et al. Allergy 2022.; (2) Maurer M, et al. Allergy 2011.; (3) Metz M, et al. Clin Rev Allergy Immunol 2020.; (4) Maurer M, et al. Clin Exp Allergy 2020.; (5) Youngblood BA, et al. Int Arch Allergy 2019.; (6) Youngblood BA, et al. Cells 2020.; (7) Dellon E, et al. NEJM 2020.; (8) Anesi S, et al. J Allergy Clin Immunol 2022.; (9) Altrichter S, et al. J Allergy Clin Immunol 2022.; (10) Allakos data on file.